Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Fujian Shengdi Pharmaceutical is the lead sponsor of 30 current clinical trials in our China register. 17 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are HRS9531, HRS-4729 and HRS-5635. The most-studied condition is Obesity.

ClinicalTrials.gov trials by status

Recruiting1757%
Not yet open517%
Active, closed827%

Trials by phase

Phase 21343%
Phase 1930%
Phase 3827%

Clinical trials sponsored by Fujian Shengdi Pharmaceutical

30 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis NCT07660848 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs: HRS-4729, HRS9531	Phase 2	Recruiting	2026-08	China
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B NCT06425341 · ClinicalTrials.gov ↗ · Chronic Hepatitis B Drugs: HRS-5635, PEG-IFNα	Phase 2	Recruiting	2024-06	China
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment NCT07807059 · ClinicalTrials.gov ↗ · Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus Drug: HRS-4729	Phase 1	Recruiting	2026-09	China
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects NCT07670884 · ClinicalTrials.gov ↗ · Chronic Management of Body Weight Drug: HRS9531	Phase 3	Recruiting	2026-07	China
Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B NCT07606950 · ClinicalTrials.gov ↗ · Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B Drug: HRS-5635	Phase 3	Recruiting	2026-07	China
A Single Ascending Dose of HRS-2162 in Healthy Subjects NCT07195604 · ClinicalTrials.gov ↗ · Reversal of Neuromuscular Blockade	Phase 1	Recruiting	2025-09	China
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection NCT06934408 · ClinicalTrials.gov ↗ · Obesity, Overweight	Phase 1	Recruiting	2025-05	China
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects NCT07150962 · ClinicalTrials.gov ↗ · Overweight or Obesity	Phase 1	Recruiting	2025-10	China
A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus NCT07599410 · ClinicalTrials.gov ↗ · T2DM Drug: HRS9531	Phase 2	Recruiting	2026-07	China
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function NCT07540754 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Weight Loss Drug: HRS9531	Phase 1	Recruiting	2026-05	China
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention NCT07318103 · ClinicalTrials.gov ↗ · Fluid Retention Caused by Heart Failure	Phase 2	Recruiting	2025-12	China
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy NCT06994650 · ClinicalTrials.gov ↗ · Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy Drug: HRS9531	Phase 3	Recruiting	2025-08	China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity NCT07559136 · ClinicalTrials.gov ↗ · Overweight and Obesity	Phase 1	Recruiting	2026-06	China
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity NCT06974851 · ClinicalTrials.gov ↗ · Bstructive Sleep Apnea (OSA) and Obesity Drug: HRS9531	Phase 3	Recruiting	2025-07	China
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin NCT07060456 · ClinicalTrials.gov ↗ · Type 2 Diabetes	Phase 3	Recruiting	2025-07	China
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease NCT07551492 · ClinicalTrials.gov ↗ · Atherosclerotic Cardiovascular Disease	Phase 3	Recruiting	2026-05	China
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting NCT07709897 · ClinicalTrials.gov ↗ · Prevention of Postoperative Nausea and Vomiting Drug: Palonosetron hydrochloride	Phase 2	Recruiting	2026-08	China
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants NCT07802964 · ClinicalTrials.gov ↗ · Psoriasis Vulgaris	Phase 1	Not yet open	2026-09	China
A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis NCT07709910 · ClinicalTrials.gov ↗ · Participants With Obesity and Knee Osteoarthritis Drug: Ribupatide	Phase 3	Not yet open	2026-07	China
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity NCT07690826 · ClinicalTrials.gov ↗ · Overweight or Obesity Drug: HRS-4729	Phase 2	Not yet open	2026-07	China
A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants NCT06506175 · ClinicalTrials.gov ↗ · Weight Management, Type 2 Diabetes Drug: HRS9531	Phase 1	Not yet open	2026-07	China
A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia NCT07799688 · ClinicalTrials.gov ↗ · Hyperlipidemia Drug: HRS-7249	Phase 2	Not yet open	2026-09	China
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction NCT06391710 · ClinicalTrials.gov ↗ · Heart Failure With Preserved Ejection Fraction Drug: HRS9531	Phase 2	Active, closed	2024-05	China
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity NCT07285902 · ClinicalTrials.gov ↗ · Obesity Drugs: HRS9531, Semaglutide	Phase 3	Active, closed	2025-12	China
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis NCT07308392 · ClinicalTrials.gov ↗ · Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis	Phase 2	Active, closed	2026-02	China
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia NCT07100418 · ClinicalTrials.gov ↗ · Hyperlipidemia Drug: HRS-7249	Phase 2	Active, closed	2025-08	China
HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. NCT07233070 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke	Phase 2	Active, closed	2025-10	China
A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants NCT07681479 · ClinicalTrials.gov ↗ · Fluid Retention Due to Heart Failure	Phase 1	Active, closed	2026-08	China
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension NCT07297797 · ClinicalTrials.gov ↗ · Mild to Moderate Hypertension	Phase 2	Active, closed	2026-01	China
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events NCT07185776 · ClinicalTrials.gov ↗ · Lipoprotein Disorder	Phase 2	Active, closed	2025-10	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Fujian Shengdi Pharmaceutical trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

HRS95319 HRS-47293 HRS-56352 HRS-72492 PEG-IFNα1 Palonosetron hydrochloride1 Ribupatide1 Semaglutide1

Conditions in Fujian Shengdi Pharmaceutical trials

31 conditions

Obesity2 Overweight or Obesity2 Hyperlipidemia2 Type 2 Diabetes2Metabolic Dysfunction-Associated Steatohepatitis (MASH)1Psoriasis Vulgaris1Chronic Hepatitis B1 Overweight/Obesity1Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)1Type 2 Diabetes Mellitus1Participants With Obesity and Knee Osteoarthritis1Chronic Management of Body Weight1Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B1Heart Failure With Preserved Ejection Fraction1Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis1Reversal of Neuromuscular Blockade1Overweight1Weight Management1T2DM1 Acute Ischemic Stroke1 Diabetes Mellitus1 Weight Loss1Fluid Retention Caused by Heart Failure1Fluid Retention Due to Heart Failure1

By trial register

Register	Trials	Recruiting
Clinical trials in China	30	17

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Obesity

Sponsor	Trials
Eli Lilly and Company	39
Novo Nordisk	39
Amgen	7
China-Japan Friendship Hospital	6
Kailera	5
Innovent Biologics (Suzhou)	5
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	4
Hangzhou Sciwind Biosciences	4
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	3
Peking University Third Hospital	3

Sponsors with the most current trials registered for this condition.

Questions about Fujian Shengdi Pharmaceutical trials

How many clinical trials does Fujian Shengdi Pharmaceutical sponsor?

Fujian Shengdi Pharmaceutical is the lead sponsor of 30 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Fujian Shengdi Pharmaceutical trials recruiting?

Yes. 17 of its 30 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fujian Shengdi Pharmaceutical testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are HRS9531 (9), HRS-4729 (3), HRS-5635 (2), HRS-7249 (2) and PEG-IFNα (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Fujian Shengdi Pharmaceutical clinical trials